EXPERT PERSPECTIVE VIRTUAL TUMOR BOARD
Alicia Morgans, MD:Let’s move on to our next case.
Jorge Garcia, MD:Great, Alicia, thank you.
This is a 64-year-old white man who, in May 2018, was referred to urology with some urinary tract symptomsspecifically urinary hesitancy, decreased urinary flow, and some intermittent back pain usually relieved with over-the-counter NSAIDs [nonsteroidal anti-inflammatory drugs]. His PSA [prostate-specific antigen] at the time was found to be elevated at around 130 ng/mL. His family history: He had CHF [congestive heart failure], heart disease, and hypertension. His rectal exam at the time was a firm gland, but no masses or nodules were found.
He finally undergoes a 12-core sextant biopsy and has high-volume disease. Ten of 12 cores with positive disease, with a Group 4 or a Gleason 4+4. He undergoes a CT [computed tomography] scan of the abdomen and pelvic region and is found to have multiple lymph node metastases, specifically retroperitoneal lymphadenopathythe largest, 2.5 cm. A technetium bone scan also demonstrated the presence of multiple bone lesions in the axial skeleton, sacrum, ribs, left femur, and scapula. And his ECOG performance status was 1.
So really, this is a guy who is walking in the office with de novo metastatic disease. Whatever definition one follows, whether you use the French or the American definition, he does have high-volume disease.
Transcript edited for clarity.
Novel Frontline Treatments Add Layer of Complexity in Urothelial Carcinoma
January 2nd 2025The past 12 months have seen the FDA approvals of enfortumab vedotin plus pembrolizumab for patients with locally advanced or metastatic urothelial cancer and nivolumab plus cisplatin and gemcitabine for patients with unresectable or metastatic urothelial carcinoma.
Read More
Cusnir Explores Impact of ARANOTE Data on ARPI Plus ADT Use in mHSPC
December 31st 2024During an in-person Community Case Forum event in Miami, Florida, Mike Cusnir, MD, discussed the ARANOTE study outcomes presented at ESMO 2024 and how they fit into the treatment paradigm for patients with metastatic hormone-sensitive prostate cancer.
Read More